CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Gilead hikes full-year sales outlook, quarterly HIV sales rise 18%

By Reuters News

By Deena Beasley

Oct 29 (Reuters) - Gilead Sciences GILD.O hiked its full-year sales outlook on Thursday and reported third-quarter product sales rose 13%, driven by a double-digit percentage jump for its flagship HIV drug franchise.

The company reported quarterly adjusted earnings of $2.55 per share on revenue of $8.3 billion, beating the average analysts' estimates of $2.19 a share and $7.8 billion in revenue, according to LSEG data.

Foster City, California-based Gilead said an 18% increase in HIV sales to $6.2 billion in the quarter was mainly driven by higher prices, higher demand for HIV prevention drugs and favorable inventory dynamics.

Sales of HIV drug Biktarvy rose 10% to $4.1 billion, beating analyst expectations of $3.86 billion.

Gilead said the US Centers for Medicare & Medicaid Services completed the process of setting a new "maximum fair price" for Biktarvy to take effect January 1, 2028 for purchases made by the Medicare health program for people age 65 and over. The HIV drug was one of 15 medications selected for the third round of annual price negotiations under the Inflation Reduction Act of 2022.

For 2026, Gilead said it now expects product sales of $31 billion to $31.3 billion, up from a previous estimate of $30.1 billion to $30.4 billion.

The drugmaker, however, also increased its estimated full-year adjusted loss per share to between $1.20 and $0.85, from a previous range of $0.65 to $0.30, citing the impact of $12.4 billion in deal-related charges.

Third-quarter sales for the company's liver disease portfolio rose 13% to $927 million.

Gilead said cell therapy sales decreased 18% to $355 million, reflecting ongoing competition, while sales of cancer drug Trodelvy rose 42% to $506 million, primarily driven by higher demand.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.